|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal AL: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sexton RE, Al Hallak MN, Diab M and Azmi
AS: Gastric cancer: A comprehensive review of current and future
treatment strategies. Cancer Metastasis Rev. 39:1179–1203. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar
|
|
4
|
Ling Q, Huang ST, Yu TH, Liu HL, Zhao LY,
Chen XL, Liu K, Chen XZ, Yang K, Hu JK, et al: Optimal timing of
surgery for gastric cancer after neoadjuvant chemotherapy: A
systematic review and meta-analysis. World J Surg Oncol.
21:3772023. View Article : Google Scholar
|
|
5
|
Merchant SJ, Kong W, Mahmud A, Booth CM
and Hanna TP: Palliative radiotherapy for esophageal and gastric
cancer: Population-based patterns of utilization and outcomes in
Ontario, Canada. J Palliat Care. 38:157–166. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haggstrom L, Chan WY, Nagrial A, Chantrill
LA, Sim HW, Yip D and Chin V: Chemotherapy and radiotherapy for
advanced pancreatic cancer. Cochrane Database Syst Rev.
12:CD0110442024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan SY and Fan JG: Application of immune
checkpoint inhibitors and microsatellite instability in gastric
cancer. World J Gastroenterol. 30:2734–2739. 2024. View Article : Google Scholar
|
|
8
|
Nie Y, Schalper KA and Chiang A:
Mechanisms of immunotherapy resistance in small cell lung cancer.
Cancer Drug Resist. 7:552024.
|
|
9
|
Xu W, Li B, Xu M, Yang T and Hao X:
Traditional Chinese medicine for precancerous lesions of gastric
cancer: A review. Biomed Pharmacother. 146:1125422022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Y, Huang T, Wang L, Wang Y, Liu Y, Bai
J, Wen X, Li Y, Long K and Zhang H: Traditional Chinese Medicine in
the treatment of chronic atrophic gastritis, precancerous lesions
and gastric cancer. J Ethnopharmacol. 337:1188122025. View Article : Google Scholar
|
|
11
|
Dai Z, Tan C, Wang J, Wang Q, Wang Y, He
Y, Peng Y, Gao M, Zhang Y, Liu L, et al: Traditional Chinese
medicine for gastric cancer: An evidence mapping. Phytother Res.
38:2707–2723. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao S, Xu T, Wang W, Li J, Shan Y, Wang Y
and Tan H: Polysaccharides from Anemarrhena asphodeloides Bge, the
extraction, purification, structure characterization, biological
activities and application of a traditional herbal medicine. Int J
Biol Macromol. 311:1434972025. View Article : Google Scholar
|
|
13
|
Gao S, Wang Y, Shan Y, Wang W, Li J and
Tan H: Rhizoma Coptidis polysaccharides: Extraction, separation,
purification, structural characteristics and bioactivities. Int J
Biol Macromol. 320:1456772025. View Article : Google Scholar
|
|
14
|
Wang G, Huang Y, Zhou L, Yang H, Lin H,
Zhou S, Tan Z and Qian J: Immunotherapy and targeted therapy as
first-line treatment for advanced gastric cancer. Crit Rev Oncol
Hematol. 198:1041972024. View Article : Google Scholar
|
|
15
|
Zhang X, Yang L, Liu S, Cao LL, Wang N, Li
HC and Ji JF: Interpretation on the report of global cancer
statistics 2022. Zhonghua Zhong Liu Za Zhi. 46:710–721. 2024.(In
Chinese).
|
|
16
|
Inamoto R, Takahashi N and Yamada Y:
Claudin18.2 in advanced gastric cancer. Cancers (Basel).
15:57422023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sahin U, Koslowski M, Dhaene K, Usener D,
Brandenburg G, Seitz G, Huber C and Türeci O: Claudin-18 splice
variant 2 is a pan-cancer target suitable for therapeutic antibody
development. Clin Cancer Res. 14:7624–7634. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baek JH, Park DJ, Kim GY, Cheon J, Kang
BW, Cha HJ and Kim JG: Clinical implications of claudin18.2
expression in patients with gastric cancer. Anticancer Res.
39:6973–6979. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bunga OD and Danilova NV: Claudin-18.2 and
gastric cancer: From physiology to carcinogenesis. Arkh Patol.
86:92–99. 2024.(In Russian). View Article : Google Scholar
|
|
20
|
Mathias-Machado MC, de Jesus VHF, Jácome
A, Donadio MD, Aruquipa MPS, Fogacci J, Cunha RG, da Silva LM and
Peixoto RD: Claudin 18.2 as a new biomarker in gastric cancer-what
should we know? Cancers (Basel). 16:6792024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakayama I, Qi C, Chen Y, Nakamura Y, Shen
L and Shitara K: Claudin 18.2 as a novel therapeutic target. Nat
Rev Clin Oncol. 21:354–369. 2024. View Article : Google Scholar
|
|
22
|
Tojjari A, Idrissi YA and Saeed A:
Emerging targets in gastric and pancreatic cancer: Focus on claudin
18.2. Cancer Lett. 611:2173622024. View Article : Google Scholar
|
|
23
|
Seckin Y, Arici S, Harputluoglu M, Yonem
O, Yilmaz A, Ozer H, Karincaoglu M and Demirel U: Expression of
claudin-4 and beta-catenin in gastric premalignant lesions. Acta
Gastroenterol Belg. 72:407–412. 2009.PubMed/NCBI
|
|
24
|
Konno H, Lin T, Wu R, Dai X, Li S, Wang G,
Chen M, Li W, Wang L, Sun BC, et al: ZL-1211 exhibits robust
antitumor activity by enhancing ADCC and activating NK
Cell-mediated inflammation in CLDN18.2-High and -Low expressing
gastric cancer models. Cancer Res Commun. 2:937–950. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kubota Y, Kawazoe A, Mishima S, Nakamura
Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, et al:
Comprehensive clinical and molecular characterization of claudin
18.2 expression in advanced gastric or gastroesophageal junction
cancer. ESMO Open. 8:1007622023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Castillo DR, Guo M, John Kim K II, Zhong
H, Brar G, Wu S, Mannan R, Cecilia Lau S, Xing Y and Peter Wu S:
Association of Claudin18.2 expression, PD-L1, and prognostic
implications in gastric and gastroesophageal junction cancers. J
Clin Oncol. 43:e160942025. View Article : Google Scholar
|
|
27
|
Wang C, Wang Y, Chen J, Wang Y, Pang C,
Liang C, Yuan L and Ma Y: CLDN18.2 expression and its impact on
prognosis and the immune microenvironment in gastric cancer. BMC
Gastroenterol. 23:2832023. View Article : Google Scholar
|
|
28
|
Rha SY, Kwon WS, Lee CK, Jung M, Shin S
and Kim H, Park S, Yoo JH and Kim H: Co-expressing pattern of
multiple biomakers and dynamic change of Claudin18.2 expression
after systemic chemotherapy in advanced gastric cancer. J Clin
Oncol. 43:40372025. View Article : Google Scholar
|
|
29
|
Lordick F, Van Cutsem E, Shitara K, Xu RH,
Ajani JA, Shah MA, Oh M, Ganguli A, Chang L, Rhoten S, et al:
Health-related quality of life in patients with CLDN18.2-positive,
locally advanced unresectable or metastatic gastric or
gastroesophageal junction adenocarcinoma: Results from the
SPOTLIGHT and GLOW clinical trials. ESMO Open. 9:1036632024.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim HD, Choi E, Shin J, Lee IS, Ko CS, Ryu
MH and Park YS: Clinicopathologic features and prognostic value of
claudin 18.2 overexpression in patients with resectable gastric
cancer. Sci Rep. 13:200472023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pellino A, Brignola S, Riello E, Niero M,
Murgioni S, Guido M, Nappo F, Businello G, Sbaraglia M, Bergamo F,
et al: Association of CLDN18 protein expression with
clinicopathological features and prognosis in advanced gastric and
gastroesophageal junction adenocarcinomas. J Pers Med. 11:10952021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Waters R, Sewastjanow-Silva M, Yamashita
K, Abdelhakeem A, Iwata KK, Moran D, Elsouda D, Guerrero A, Pizzi
M, Vicentini ER, et al: Retrospective study of claudin 18 isoform 2
prevalence and prognostic association in gastric and
gastroesophageal junction adenocarcinoma. JCO Precis Oncol.
8:e23005432024. View Article : Google Scholar
|
|
33
|
Ungureanu BS, Lungulescu CV, Pirici D,
Turcu-Stiolica A, Gheonea DI, Sacerdotianu VM, Liliac IM, Moraru E,
Bende F and Saftoiu A: Clinicopathologic relevance of claudin 18.2
expression in gastric cancer: A Meta-analysis. Front Oncol.
11:6438722021. View Article : Google Scholar
|
|
34
|
Gao J, Wang Z, Jiang W, Zhang Y, Meng Z,
Niu Y, Sheng Z, Chen C, Liu X, Chen X, et al: CLDN18.2 and 4-1BB
bispecific antibody givastomig exerts antitumor activity through
CLDN18.2-expressing tumor-directed T-cell activation. J Immunother
Cancer. 11:e0067042023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Optimism Surrounds Claudin 18.2 ADC.
Cancer Discov. 14:122024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li D, Ding L, Chen Y, Wang Z, Zeng Z, Ma
X, Huang H, Li H, Qian X, Yang Z and Zhu H: Exploration of
radionuclide labeling of a novel scFv-Fc fusion protein targeting
CLDN18.2 for tumor diagnosis and treatment. Eur J Med Chem.
266:1161342024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sahin U, Türeci Ö, Manikhas G, Lordick F,
Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B,
et al: FAST: A randomised phase II study of zolbetuximab (IMAB362)
plus EOX versus EOX alone for first-line treatment of advanced
CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Ann Oncol. 32:609–619. 2021. View Article : Google Scholar
|
|
38
|
Shitara K, Kawazoe A, Hirakawa A,
Nakanishi Y, Furuki S, Fukuda M, Ueno Y, Raizer J and Arozullah A:
Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+
gastric or gastroesophageal junction adenocarcinoma. Cancer Sci.
114:1606–1615. 2023. View Article : Google Scholar
|
|
39
|
Klempner SJ, Lee KW, Shitara K, Metges JP,
Lonardi S, Ilson DH, Fazio N, Kim TY, Bai LY, Moran D, et al:
ILUSTRO: Phase II multicohort trial of zolbetuximab in patients
with advanced or metastatic claudin 18.2-Positive gastric or
gastroesophageal junction adenocarcinoma. Clin Cancer Res.
29:3882–3891. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
O'Brien NA, McDermott MSJ, Zhang J, Gong
KW, Lu M, Hoffstrom B, Luo T, Ayala R, Chau K, Liang M, et al:
Development of a novel CLDN18.2-directed monoclonal antibody and
antibody-drug conjugate for treatment of CLDN18.2-positive cancers.
Mol Cancer Ther. 22:1365–1375. 2023. View Article : Google Scholar
|
|
41
|
Zeng Z, Li L, Tao J, Liu J, Li H, Qian X,
Yang Z and Zhu H: [177Lu]Lu-labeled anti-claudin-18.2
antibody demonstrated radioimmunotherapy potential in gastric
cancer mouse xenograft models. Eur J Nucl Med Mol Imaging.
51:1221–1232. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dumontet C, Reichert JM, Senter PD,
Lambert JM and Beck A: Antibody-drug conjugates come of age in
oncology. Nat Rev Drug Discov. 22:641–661. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu X, Zhu Y, Deng X, Kong F, Xi C, Luo Q
and Zhu X: Development of a supermolecular Radionuclide-drug
conjugate system for integrated radiotheranostics for Non-small
cell lung cancer. J Med Chem. 67:11152–11167. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chau CH, Steeg PS and Figg WD:
Antibody-drug conjugates for cancer. Lancet. 394:793–804. 2019.
View Article : Google Scholar
|
|
45
|
Zhou L, Lu Y, Liu W, Wang S, Wang L, Zheng
P, Zi G, Liu H, Liu W and Wei S: Drug conjugates for the treatment
of lung cancer: From drug discovery to clinical practice. Exp
Hematol Oncol. 13:262024. View Article : Google Scholar
|
|
46
|
Khongorzul P, Ling CJ, Khan FU, Ihsan AU
and Zhang J: Antibody-drug conjugates: A comprehensive review. Mol
Cancer Res. 18:3–19. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhou KI, Strickler JH and Chen H:
Targeting Claudin-18.2 for cancer therapy: Updates from 2024 ASCO
annual meeting. J Hematol Oncol. 17:732024. View Article : Google Scholar
|
|
48
|
Yeh CL, Pai MH, Li CC, Tsai YL and Yeh SL:
Effect of arginine on angiogenesis induced by human colon cancer:
In vitro and in vivo studies. J Nutr Biochem. 21:538–543. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kinjo K, Kizaki M, Muto A, Fukuchi Y,
Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, et al:
Arsenic trioxide (As2O3)-induced apoptosis and differentiation in
retinoic acid-resistant acute promyelocytic leukemia model in
hGM-CSF-producing transgenic SCID mice. Leukemia. 14:431–438. 2000.
View Article : Google Scholar
|
|
50
|
Yao Y, Ren Y, Hou X, Zhu J, Ma X, Liu S,
Liu T, Zhang Q, Ma X, Yang Z, et al: Construction and preclinical
evaluation of a zirconium-89 labelled monoclonal antibody targeting
PD-L2 in lung cancer. Biomed Pharmacother. 168:1156022023.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Du H, Hao X, Lin B, Tang M, Wang D, Yang
X, Wang J, Qin L, Yang Y and Du X: 177Lu-labeled anticlaudin 6
monoclonal antibody for targeted therapy in esophageal cancer. J
Nucl Med. 66:377–384. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zheng L, Li C, Yang X, Liu J, Wang G, Zhou
Z, Zhu X, Gong J and Yang J: GD2-targeted theranostics of
neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8.
Eur J Nucl Med Mol Imaging. 52:1764–1777. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Drago JZ, Modi S and Chandarlapaty S:
Unlocking the potential of antibody-drug conjugates for cancer
therapy. Nat Rev Clin Oncol. 18:327–344. 2021. View Article : Google Scholar
|
|
54
|
Baah S, Laws M and Rahman KM:
Antibody-Drug Conjugates-A tutorial review. Molecules. 26:29432021.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen YF, Xu YY, Shao ZM and Yu KD:
Resistance to antibody-drug conjugates in breast cancer: mechanisms
and solutions. Cancer Commun (Lond). 43:297–337. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Díaz-Rodríguez E, Gandullo-Sánchez L,
Ocaña A and Pandiella A: Novel ADCs and strategies to overcome
resistance to Anti-HER2 ADCs. Cancers (Basel). 14:1542021.
View Article : Google Scholar
|
|
57
|
Jain RK: Normalizing tumor
microenvironment to treat cancer: bench to bedside to biomarkers. J
Clin Oncol. 31:2205–2218. 2013. View Article : Google Scholar
|
|
58
|
Beckers C, Pruschy M and Vetrugno I: Tumor
hypoxia and radiotherapy: A major driver of resistance even for
novel radiotherapy modalities. Semin Cancer Biol. 98:19–30. 2024.
View Article : Google Scholar
|
|
59
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Straub JM, New J, Hamilton CD, Lominska C,
Shnayder Y and Thomas SM: Radiation-induced fibrosis: Mechanisms
and implications for therapy. J Cancer Res Clin Oncol.
141:1985–1994. 2015. View Article : Google Scholar
|
|
61
|
Yamamoto K, Nakayama I and Shitara K: A
new molecular targeted agent for gastric Cancer-The Anti-Claudin
18.2 antibody, zolbetuximab. Gan To Kagaku Ryoho. 51:1111–1118.
2024.(In Japanese). PubMed/NCBI
|
|
62
|
Liu Y, Wang X, Zhang N, He S, Zhang J, Xu
X and Song S: Utility of 131I-HLX58-Der for the precision
treatment: Evaluation of a preclinical
radio-antibody-drug-conjugate approach in mouse models. Int J
Nanomedicine. 20:723–739. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chang HL, Schwettmann B, McArthur HL and
Chan IS: Antibody-drug conjugates in breast cancer: Overcoming
resistance and boosting immune response. J Clin Invest.
133:e1721562023. View Article : Google Scholar
|
|
64
|
Jiao J, Qian Y, Lv Y, Wei W, Long Y, Guo
X, Buerliesi A, Ye J, Han H, Li J, et al: Overcoming limitations
and advancing the therapeutic potential of antibody-oligonucleotide
conjugates (AOCs): Current status and future perspectives.
Pharmacol Res. 209:1074692024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Shah MA, Shitara K, Ajani JA, Bang YJ,
Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J,
Huang J, et al: Zolbetuximab plus CAPOX in CLDN18.2-positive
gastric or gastroesophageal junction adenocarcinoma: The
randomized, phase 3 GLOW trial. Nat Med. 29:2133–2141. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Shitara K, Shah MA, Lordick F, Van Cutsem
E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, Yamaguchi K,
et al: Zolbetuximab in gastric or gastroesophageal junction
adenocarcinoma. N Engl J Med. 391:1159–1162. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hammood M, Craig AW and Leyton JV: Impact
of endocytosis mechanisms for the receptors targeted by the
currently approved Antibody-drug conjugates (ADCs)-A necessity for
future ADC research and development. Pharmaceuticals (Basel).
14:6742021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang S, Wang X, Gao X, Chen X, Li L, Li
G, Liu C, Miao Y, Wang R and Hu K: Radiopharmaceuticals and their
applications in medicine. Signal Transduct Target Ther. 10:12025.
View Article : Google Scholar : PubMed/NCBI
|
![(A) Flow chart of the experimental
design. Created with BioRender.com. (B) Flow cytometry was used to
detect CLDN18.2 expression in NUGC-4-CLDN18.2 cells. Blue line:
Anti-SYSA1801mAb (PE); red line: isotype control (PE). (C)
Radiochemical purity of [177Lu]Lu-DOTA-SYSA1801mAb
determined by HPLC was >99%. Upper panel: Radio-HPLC
(177Lu γ-radiation detection); lower panel:
Ultraviolet-HPLC (254 nm absorption detection). (D) Specific
binding of [177Lu]Lu-DOTA-SYSA1801mAb in NUGC-4-CLDN18.2
cells. Left panel: Saturation binding curve plotted on a
logarithmic concentration scale for calculation of the equilibrium
dissociation constant (Kd). Right panel: Saturation binding curve
plotted on a linear concentration scale for determination of the
maximum binding capacity (Bmax). (E) Stability of
[177Lu]Lu-DOTA-SYSA1801mAb detected by thin-layer
chromatography in normal saline and 1640 (10% FBS). ADC,
antibody-drug conjugate; CLDN18.2, claudin 18.2; EC50,
half maximal effective concentration; FBS, fetal bovine serum;
HPLC, high-performance liquid chromatography; mAb, monoclonal
antibody; RDC, radionuclide-drug conjugate.](/article_images/or/55/1/or-55-01-09009-g00.jpg)
![(A) Positron emission
tomography-computed tomography images showing tumor-specific
accumulation of [89Zr]Zr-DFO-SYSA1801mAb in
tumor-bearing mice over time, in contrast to that in other
non-target tissues. (B) Quantitative region of interest analysis of
the tumor, heart, liver, spleen, kidney, and muscle in
tumor-bearing mice at 4, 24, 48, 96, 144 and 192 h after injection
of [89Zr]Zr-DFO-SYSA1801mAb. (C) Biodistribution results
at 4, 24, 48, 96 and 144 h after injection of
[177Lu]Lu-DOTA-SYSA1801mAb. (D) Tumor-to-blood, (E)
tumor-to-liver and (F) tumor-to-kidney ratios at 4, 24, 48, 96 and
144 h after injection of [177Lu]Lu-DOTA-SYSA1801mAb.
Data are presented as the mean ± SD. Statistical differences across
the different time points for each ratio were determined by one-way
analysis of variance followed by Tukey's post hoc test for multiple
comparisons. *P<0.05, **P<0.01, ***P<0.001. %DI/g,
percentage of injected dose per gram of tissue; mAb, monoclonal
antibody.](/article_images/or/55/1/or-55-01-09009-g01.jpg)
